STAT
APRIL 4, 2024
It began with injecting monkeys with sewage to see if they developed polio. Building off that early polio work from the 1940s, researchers from the Baylor College of Medicine analyzed public wastewater and showed they could detect over 450 disease-causing viruses. Their study demonstrating the power of sewage as an early-warning system for outbreaks won the 2024 STAT Madness popular vote.
PharmaVoice
APRIL 4, 2024
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 4, 2024
Humans have long tinkered with the evolutionary trajectories of other species. Thousands of years ago we tamed wolves into dogs and transformed a wild grass into the agricultural wonder wheat. Within the past few centuries, we exterminated the Tasmanian tiger and doomed the dodo bird to oblivion. Now, we stand on the brink of an ambitious new era in how humans may transfigure life around us: by pursuing the science of de-extinction, or the resurrection of species once lost to this world.
pharmaphorum
APRIL 4, 2024
Discover how AI-powered real-world evidence generation is revolutionising the biotech industry, providing valuable insights for biopharma companies to make informed decisions. Learn more about the impact of RWD on biotechs.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
APRIL 4, 2024
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease. Relyvrio was approved by the Food and Drug Administration in 2022 , based on data that showed a modest slowing of disease progression. The approval was contentious — regulators initially advised Amylyx not to file for approval until it had conducted another test, but ultimately cleared the drug.
Express Pharma
APRIL 4, 2024
First phase with a builtup area of 29,000 square meters to be completed within a year, second phase by 2026 Gujarat-based SAVA Healthcare conducted the ground-breaking ceremony of its second manufacturing plant, in the Smart Industrial Park (SIP) of Madhya Pradesh Industry Development Corporation (MPIDC) in March. This green field project will expand the manufacturing capabilities of SAVA Healthcare as well as create 1000+ job opportunities, offering advanced skill development for the local tale
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
APRIL 4, 2024
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug class.
STAT
APRIL 4, 2024
Here’s just the tip of the iceberg: $722.50 for a nurse to push a drug into an IV. $21,500 for ten stitches. The prices charged by hospitals are exorbitant and rising. Private health insurance premiums paid by working age adults are rising rapidly. Many Americans skip necessary medical care, while those who do get treated can end up bankrupt.
Pharmafile
APRIL 4, 2024
Basilea Pharmaceutica has announced that the US Food and Drug Administration (FDA) has approved Zevtera (ceftobiprole medocaril sodium for injection), as a new antibiotic for three indications. The drug is approved for the treatment of adult patients with Staphylococcus aureus bloodstream infections (SAB), including patients who have right-sided infective endocarditis, adult patients with acute bacterial […] The post FDA approves Basilea’s antibiotic Zevtera for three indications appeared
STAT
APRIL 4, 2024
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. Some employees may find positions elsewhere in the company, but they are mostly being pulled from the field.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
APRIL 4, 2024
Healthcare system Providence has spun out a new company, Praia Health, focused on a platform to build and sustain connections between patients and health providers. The new company starts life with $20 million in Series A funding and a mission to develop the Praia Health Identity and Engagement Platform, which was launched within Providence’s digital innovation group (DIG) incubator in 2022 and already handles around 3.5 million user accounts.
STAT
APRIL 4, 2024
The oversight division of a U.S. government agency tasked with ensuring the safe use of radioactive materials issued a recent report that the agency’s advisers had key undisclosed conflicts of interest, raising fresh concerns about controversial decisions around the reporting of radioactive injection accidents. The report, released on March 26 and conducted by the Nuclear Regulatory Commission’s (NRC) Office of the Inspector General, identified conflicts of interest involving two m
BioPharma Dive
APRIL 4, 2024
A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.
STAT
APRIL 4, 2024
For more than a century, the United States has been the undisputed leader in medical and biotechnology innovation. It saved millions of lives by mass-producing the first polio vaccines. U.S. researchers discovered new antibiotics that turned once-fatal infections into minor ailments, and developed antiretroviral cocktails that transformed HIV from a death sentence into a manageable, chronic disease.
Express Pharma
APRIL 4, 2024
The companies will join forces to advance the use of precision medicine on a global scale SOPHiA GENETICS, a cloud-native software company in the healthcare space has announced a strategic partnership with Strand Life Sciences to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and inno
STAT
APRIL 4, 2024
Many of the effects of climate change play out at a very large scale: Heatwaves that grip entire continents. Flooding that submerges vast swaths of island nations and continental coastal areas. Other effects are far less visible because they’re taking place inside people’s bodies. That doesn’t make them any less dangerous.
pharmaphorum
APRIL 4, 2024
Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial. The company said that it was stopping access to the drug for new patients immediately, while those already taking it would be able to continue on it via a free drug programme, after consultation with their doctors – a move that has garnered praise from across the biopharma industry.
STAT
APRIL 4, 2024
Cochlear implants have successfully improved hearing loss for decades, but few people who qualify for an implant actually get it. Even in countries with universal healthcare, the adoption rates are dismal. Researchers are finding further disparities for marginalized communities, especially for Black and Asian patients, according to a recent study of British hospitals published Thursday in PLOS Medicine.
pharmaphorum
APRIL 4, 2024
Last week, pharmaphorum editor-in-chief Jonah Comstock travelled to Philadelphia for Reuters Pharma USA. On today’s podcast, he chats with guest host and Deep Dive editor Eloise McLellan about his biggest takeaways from the two-day event.
STAT
APRIL 4, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. First the news: Glen Tullman, currently the CEO Transcarent , has a new, roughly $100 million venture fund, called 62 Ventures.
Pharma Times
APRIL 4, 2024
The fatal, progressive neurological condition currently affects around 5,000 people in the UK
STAT
APRIL 4, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey, it’s Meghana. Today, we see how the GLP-1s might be harnessed for Parkinson’s, we learn about species de-extinction efforts, and BIO’s CEO tells us why the U.S. needs to stay on top in biotech.
European Pharmaceutical Review
APRIL 4, 2024
A new £17.9 million initiative announced on 21 March is set to accelerate advanced therapy development in the UK. The scheme aims to support UK advanced therapy medicinal product (ATMP) clinical trials. UK Health Minister Andrew Stephenson commented on the news, stating that the investment “reaffirms the UK’s position as a global leader in clinical research”.
STAT
APRIL 4, 2024
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Bankruptcies, restructurings, clinical trial setbacks, and falling stock prices: It’s been a disconcerting week in Biotech Land. Luckily, this newsletter has arrived like a warm hug.
The Pharmacist
APRIL 4, 2024
Practice pharmacists in Northern Ireland will be ‘more firmly established’ as the ‘clinical leads for medicines’ within general practice teams by 2030, a new government strategy has pledged. The Department of Health in Northern Ireland has published a strategy for the ‘future development’ of the general practice pharmacy sector after an evaluation of the service […] The post Strategy pledges pharmacists as ‘medicine leaders’ in GP practices appeared first on The Pharmacist.
STAT
APRIL 4, 2024
Top of the morning to you, and a fine one it is. After two days of downpours and strong winds, the Pharmalot campus is now enveloped by sunny skies and pleasant breezes, which is very much a welcome change. To celebrate, we are quaffing cups of stimulation. Our choice today is toasted coconut. As always, you are invited to join us. Meanwhile, we are proud to present our latest list of interesting items for you to peruse.
European Pharmaceutical Review
APRIL 4, 2024
US radiopharmacy network RLS Radiopharmacies is expanding its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by establishing a partnership with global isotope technology company Eckert & Ziegler. As part of the agreement, all 31 of RLS’ radiopharmacies will be produce Gallium-68-based (Ga-68) radiopharmaceuticals by the end of June, the company confirmed.
STAT
APRIL 4, 2024
A federal judge this week dealt a major and likely decisive blow to Safehouse, a Philadelphia nonprofit seeking to open a facility for supervised drug consumption. In a ruling on Wednesday, U.S. District Court Judge Gerald McHugh dismissed the nonprofit’s lawsuit, concluding that Safehouse was not a religious entity and therefore could not claim exemptions to drug laws under the Religious Freedom Restoration Act.
Pharma Times
APRIL 4, 2024
The project will assist researchers and companies in training the technology for healthcare settings
STAT
APRIL 4, 2024
Why is it surprising when drug executives stay true to their word? And can neoantigen cancer vaccines work? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Oruka Therapeutics CEO Lawrence Klein joins us to discuss how his company raised its first round of financing before competing with major players in the inflammation space.
Express Pharma
APRIL 4, 2024
Zena Health plans to strengthen its reach and democratise healthcare in Eastern India Zeno Health, omni channel platform for quality and affordable generic medicines has announced its acquisition of Kolkata-based startup Tablt Pharmacy. As part of its expansion plans, Zeno Health along with Tablt will be strengthening its reach in the states of West Bengal, Odisha, Bihar and Jharkhand.
Outsourcing Pharma
APRIL 4, 2024
In February, Trialbee announced its Omnichannel Network partnership with Massive Bio, a global leader in AI-enabled patient journey mapping platform to help better connect cancer patients with their oncologists/hematologists in clinical trials.
Welltopia Pharmacy
APRIL 4, 2024
Discover Hormone Therapy's effects on heart health: risks, benefits, and latest research insights in this essential read.
Outsourcing Pharma
APRIL 4, 2024
In an overwhelming response to the news that SimBioSys and General Inception had joined forces to use advanced AI and biophysical modeling, to gain deeper insights into tumor biology, the industry has spoken.
Express Pharma
APRIL 4, 2024
Arun Kedia, MD, VAV Lipids looks at some significant differences between liposomes and LNPs that extend beyond their intended applications, encompassing variations in morphology, composition and manufacturing processes Lipid-based formulations have been pivotal in advancing drug development and facilitating the delivery of therapeutic biomolecules and genes.
Expert insights. Personalized for you.
355 
Let's personalize your content